Containing Polysaccharide (e.g., Cellulose Sugars, Etc.) Patents (Class 424/461)
-
Patent number: 6645525Abstract: Compositions for sustained delivery of a biomolecule including an anionic polymer and a cationic polymer which ironically interact with each other and, optionally, with the biomolecule. Methods for making the compositions, including the step of combining the negatively charged polymer with the positively charged polymer to form an ionic complex are also provided. The biomolecule may be complexed with one of the polymers before it is complexed with the oppositely charged polymer. The complex is exposed to conditions that cause the formation of precipitated microcarriers, such as a change in pH or the addition of a complexing molecule. The compositions are preferably formulated into microcarriers.Type: GrantFiled: May 6, 2002Date of Patent: November 11, 2003Assignee: Sedum Laboratories, Inc.Inventor: James E. Woiszwillo
-
Patent number: 6635277Abstract: A once-a-day controlled release drug delivery system of diltiazem hydrochloride is provided, which is bioequivalent in plasma profile of Cardizem CD. The fast, medium, and slow release fractions are prepared using various compositions and weight gains. The individual fill weights are computed and then are filled into the same capsule using specialized encapsulation equipment using a triple-filling process. A preferred membrane dispersion that is used for preparing the fast release fraction contains 0.2% of sodium lauryl sulfate along with 20% of water soluble plasticizer (triethyl citrate), and 2% silicone dioxide, based on quaternary polymethacrylate on the weight basis. This combination provides an initial pulsatile burst after a lag time of 2 hours, leading to in-vivo bioequivalence. The preferred membrane dispersion that is used for preparing the medium release and the slow release fractions contain 16% of water soluble plasticizer along with 5% silicone dioxide, based on quaternary polymethacrylate.Type: GrantFiled: April 12, 2001Date of Patent: October 21, 2003Assignee: Wockhardt LimitedInventors: Vinay K. Sharma, Javed Hussain, Habil F. Khorakiwala
-
Patent number: 6630162Abstract: The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.Type: GrantFiled: November 9, 2000Date of Patent: October 7, 2003Assignee: Pharmacia ABInventors: Lisbeth Nilvebrant, Bengt Hallen, Birgitta Olsson, Jan Strombom, Torkek Gren, Anders Ringberg, Martin Wikberg
-
Patent number: 6627188Abstract: A method for reducing bacterial enteropathogens in fowl subjected to feed withdrawal, involving withdrawing feed from fowl and orally administering to the fowl an effective amount of a cocktail sufficient to reduce bacterial enteropathogens in the crop of the fowl, wherein the cocktail contains contains water, a carbohydrate (e.g., glucose, sucrose), and optionally a protein source, a vitamin source, an organic acid, an emulsifier, a mineral source, and mixtures thereof.Type: GrantFiled: October 31, 2000Date of Patent: September 30, 2003Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Arthur Hinton, Jr., Kimberly D. Ingram, Richard Jeffery Buhr
-
Patent number: 6627219Abstract: The present invention provides a oral capsule preparation, comprising a capsule prepared from a drug or the alkaline salt thereof, an oily compound or the alkaline salt thereof, an emulsifier and a polycarbon alcohol, together with an enteric coating disposed on the outer layer of the capsule; wherein said emulsifier is a composition of C6-18 organic fatty acid and an organic amine, or the mixture thereof. The invention also provides a method of preparing the oral capsule preparation of the invention.Type: GrantFiled: June 29, 2001Date of Patent: September 30, 2003Assignee: Pharmaceutical Industry Technology and Development CenterInventors: Wei-Hua Hao, Shih Min Chen
-
Patent number: 6623759Abstract: The invention relates to a stable medicament for oral administration which comprises (a) a core which contains an active ingredient selected from Omeprazole, Lansoprazole and Pantoprazole, together with customary pharmaceutical adjuvants, (b) an intermediate layer applied onto the core, and (c) a gastric juice-resistant outer layer. The intermediate layer in (b) is formed as a reactive layer in which a gastric juice-resistant polymer layer material partially neutralized with alkali with cation exchange capacity is present. Further, a method for the production of the stable medicament is disclosed.Type: GrantFiled: September 5, 2001Date of Patent: September 23, 2003Assignee: AstraZeneca ABInventors: Gerd-Ulfert Heese, Herbert Jünger, Arnim Laicher, Claudio Lorck, Thomas Profitlich, Gerd Weiss
-
Patent number: 6607747Abstract: A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder selected from the group consisting of sodium carboxymethylcellulose, hydroxypropylmethylcellulose, potassium alginate, and partially pregelatinized corn starch. A high drug load pharmaceutical composition, comprising the beadlet, with an enteric coating disposed thereon, is also provided.Type: GrantFiled: November 16, 2001Date of Patent: August 19, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Ismat Ullah, Gary J Wiley
-
Patent number: 6596308Abstract: A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation comprising (a) a water insoluble medicant, (b) a high melting fatty ester, (c) a low viscosity oil, (d) a cellulosic polymer, and (e) a non-ionic surfactant.Type: GrantFiled: August 5, 2002Date of Patent: July 22, 2003Assignee: Kos Pharmaceuticals, IncorporatedInventors: Jose Gutierrez-Rocca, Josephine Dunne, Saul A. Rios
-
Patent number: 6592895Abstract: Precursor polyhydric alcohol esters where acyl moieties originate from aliphatic homopolymer or copolymer polyesters and contain free hydroxyl at their terminal ends, are reacted to provide 2-carboxy ethenyl groups. The resulting products can be used in formation of hydrogels for drug delivery or can be reacted to attach aminoxyl radical or drug molecule residue or other biologically active agent for delivery of these, for example, from vascular stents.Type: GrantFiled: July 15, 2002Date of Patent: July 15, 2003Assignee: Cornell Research Foundation, Inc.Inventors: Meidong Lang, Chih-Chang Chu
-
Patent number: 6589552Abstract: The invention provides fenofibrate compositions comprising granulates. The granulates can comprise micronized fenofibrate, inert hydrosoluble carrier particles, hydrophilic polymers, and, optionally, surfactants.Type: GrantFiled: April 22, 2002Date of Patent: July 8, 2003Assignee: Laboratoires Fournier, S.A.Inventors: André Stamm, Pawan Seth
-
Patent number: 6589553Abstract: A once a day bupropion hydrochloride formulation is disclosed.Type: GrantFiled: February 8, 2001Date of Patent: July 8, 2003Assignee: Andrx Pharmaceuticals, Inc.Inventors: Boyong Li, Avinash Nangia, Chih Ming Chen
-
Patent number: 6586010Abstract: A process for producing agglomerates with a core/shell structure, in which i) initial agglomerates containing a first particulate solid are prepared; ii) a second particulate solid is agglomerated in the presence of the initial agglomerates with the addition of a binder liquid to give second stage agglomerates and, where appropriate, iii) an nth (n≧3) solid is agglomerated in the presence of the (n−1)th stage agglomerates with the addition of a binder liquid to give nth stage agglomerates.Type: GrantFiled: May 31, 2001Date of Patent: July 1, 2003Assignee: BASF AktiengesellschaftInventors: Werner Bertleff, Ulrich Bröckel, Helmut Fricke, Hans-Peter Harz, Reiner Witt
-
Publication number: 20030118639Abstract: A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation comprising (a) a water insoluble medicament, (b) a high melting fatty ester, (c) a low viscosity oil, (d) a cellulosic polymer, and (e) a non-ionic surfactant.Type: ApplicationFiled: August 5, 2002Publication date: June 26, 2003Inventors: Jose Gutierrez-Rocca, Josephine Dunne, Saul A. Rios
-
Patent number: 6576258Abstract: There is disclosed a method for stabilizing active substances that are unstable in acidic medium, unstable when stored for longer periods of time in the presence of water and at the same time sensitive to heating, by means of anhydrous granulation of active substances and dried pharmaceutically acceptable auxiliary substances for the preparation of pellet cores or granules. All pharmaceutically acceptable auxiliary substances employed are dried before use so that their weight loss at drying is less than 1.0% of the total weight of the pharmaceutically acceptable auxiliary substance, preferably less than 0.5%. Organic solvents used in process of anhydrous granulation should contain less than 0.2% of water. A novel pharmaceutical formulation with controlled release of active substances that are unstable in acidic medium, unstable when stored for longer periods of time in the presence of water and at the same time sensitive to heating, is disclosed as well.Type: GrantFiled: January 12, 2000Date of Patent: June 10, 2003Assignee: Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.Inventors: Bojan Kofler, Ljubomira Barbara Rebi{haeck over (c)}, Judita {haeck over (S)}irca, Peter Venturini
-
Patent number: 6576260Abstract: Disclosed herein is sustained-release formulations of tramadol comprising tramadol saccharinate coated with at least one sustained-release coating. The sustained release formulations may also contain tramadol in non-sustained release form, and other pharmaceutically acceptable excipients. Also disclosed are methods of preparation of and methods of treatment using the inventive formulations.Type: GrantFiled: February 28, 2002Date of Patent: June 10, 2003Assignee: Gruenenthal GmbHInventors: Johannes Bartholomaeus, Heinrich Kugelmann, Iris Ziegler
-
Patent number: 6572885Abstract: Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm.Type: GrantFiled: June 26, 2001Date of Patent: June 3, 2003Assignee: Euro-Celtique, S.A.Inventors: Benjamin Oshlack, Mark Chasin
-
Patent number: 6569455Abstract: The present invention relates to stable quick-release extrudates that contain low-viscosity hydroxypropylcellulose and at least one active ingredient. This invention also relates to a method for preparing said extrudates without the use of solvents as well as to the use of said extrudates in the production of quick-release preparations.Type: GrantFiled: January 9, 2002Date of Patent: May 27, 2003Assignee: Bayer AktiengesellschaftInventors: Venkata-Rangarao Kanikanti, Jürgen Sdebik
-
Publication number: 20030096001Abstract: A novel extended or controlled release encapsulated product is provided and includes: a pharmaceutically effective amount of fluoxetine HCl or mesalamine; at least one erodible polymer; and at least one lubricating material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A pulsating release product for extended release of fluoxetine is also disclosed. A method for preparing the encapsulated product is also provided.Type: ApplicationFiled: August 1, 2002Publication date: May 22, 2003Inventors: S. Rao Cherukuri, Vittorino Ravelli
-
Patent number: 6555106Abstract: The invention provides a method and compositions for controlling food borne enteric bacterial pathogens in poultry populations. The incidence of the colonization of poultry by enteropathogenic bacteria, and/or the populations of enteropathogenic bacteria within colonized poultry, may by substantially reduced by providing particles of an expanded matrix material to the locus or vicinity of the animals, particularly during the period of feed removal prior to slaughter. The method and compositions are particularly useful for the control of Salmonella species, enteropathogenic Escherichia coli, and Campylobacter species.Type: GrantFiled: February 8, 2001Date of Patent: April 29, 2003Assignee: The United States of America as represented by the Secretary of AgricultureInventors: James A. Byrd, II, Larry H. Stanker, Donald E. Corrier
-
Patent number: 6541455Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.Type: GrantFiled: January 14, 2002Date of Patent: April 1, 2003Inventor: Dale L. Pearlman
-
Patent number: 6537666Abstract: The present invention relates to methods of forming a humidity barrier using fats or other materials that can form an amorphous coating for particles comprising sensitive biological materials in a dehydrated and/or a vitrified state. Since the hydrophobic coating may be sticky, a second hard-shell coating is applied to prevent the particles from sticking together. This approach would minimize exposure of the dried biological material to atmospheric moisture and the consequent loss of biological activity.Type: GrantFiled: October 23, 2000Date of Patent: March 25, 2003Assignee: Universal Preservation Technologies, Inc.Inventor: Victor Bronshtein
-
Publication number: 20030029444Abstract: The subject of the present invention is a process for preparing pregelatinized high amylose starch, comprising the steps consisting of:Type: ApplicationFiled: March 25, 2002Publication date: February 13, 2003Inventors: Domenico Carbone, Claude Quettier, Giovanni Semino, Ernesto Fossati
-
Patent number: 6514986Abstract: The invention relates to the new arginine salt forms of S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those arginine salt forms as the active ingredient for its use in treating antimicrobial infections.Type: GrantFiled: March 9, 2001Date of Patent: February 4, 2003Assignee: Wockhardt LimitedInventors: Noel J. de Souza, Shivkumar Agarwal, Mahesh V. Patel, Satish B. Bhawsar, Rupinder K. Beri, Ravindra D. Yeole, Nitin Shetty
-
Patent number: 6503883Abstract: The invention relates to a pharmaceutical preparation, which contains an immunosuppressive active agent in dissolved form in a starch capsule, or hard or soft gelatin capsule which has been coated with one or several polymer films. The invention further relates to a process for the production of the pharmaceutical preparation.Type: GrantFiled: November 28, 2000Date of Patent: January 7, 2003Assignee: Novartis AGInventor: Ulrich Posanski
-
Patent number: 6500454Abstract: A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration—time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.Type: GrantFiled: October 4, 2001Date of Patent: December 31, 2002Assignee: Eurand Pharmaceuticals Ltd.Inventors: Phillip J. Percel, Krishna S. Vishnupad, Gopi M. Venkatesh
-
Publication number: 20020197307Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Type: ApplicationFiled: May 21, 2002Publication date: December 26, 2002Applicant: WyethInventors: Deborah M. Sherman, John C. Clark, John U. Lamer, Stephen A. White
-
Patent number: 6495163Abstract: A dry moisture barrier film coating composition for forming a moisture barrier film coating for pharmaceutical tablets and the like comprises polyvinyl alcohol, soya lecithin, and optionally a flow aid, a colorant, and/or a suspending agent. A liquid coating solution or dispersion for forming a moisture barrier film coating for pharmaceutical tablets and the like comprises polyvinyl alcohol, soya lecithin, water, and optionally a flow aid, a colorant, and/or a suspending agent. A method of coating pharmaceutical tablets and the like with a moisture barrier film coating comprises forming a liquid coating solution or dispersion for forming a moisture barrier film coating for pharmaceutical tablets and the like comprising polyvinyl alcohol, soya lecithin, water, and optionally a flow aid, a colorant, and/or a suspending agent, applying the coating solution or dispersion onto the tablets to form a film coating on the tablets, and drying the film coating on the tablets.Type: GrantFiled: September 23, 1998Date of Patent: December 17, 2002Assignee: BPSI Holdings, Inc.Inventor: Martin Philip Jordan
-
Patent number: 6482432Abstract: The present invention relates to a process for providing non-lipid, liquid form herbal extracts in a vegetable gelatin, HPMC, or any other cellulose derivative capsule. The process includes extracting an herbal plant material with an alcohol to provide an aqueous alcoholic herbal extract. The aqueous alcoholic herbal extract is contacted with sufficient glycerin to maintain the extract preferably in solution, and at least dispersed in the mixture of glycerin and aqueous alcoholic herbal extract. Alcohol and water is removed form the mixture to provide a glycerin-based liquid or semi-solid herbal extract and having a moisture content of less than 10 percent by weight, and preferably less than 5 percent by weight. The herb extract is then encapsulated in a vegetable gelatin, HPMC, or any other cellulose derivative capsule.Type: GrantFiled: February 1, 2001Date of Patent: November 19, 2002Assignee: GAIA Herbs, Inc.Inventor: Xiping Wang
-
Patent number: 6479075Abstract: This invention in general relates to novel pharmaceutical compositions for acid labile substances as well as for methods of making such. Specifically, the invention provides a pharmaceutical composition comprising about 1 to 75% by weight acid labile compound, up to about 5% by weight disintegrant, at least one protector coat layer used to separate and protect the acid labile substance from acid reacting groups and gastric juice, and at least one enteric coat layer which surrounds the protector coating layer and ensures delivery of over 80% the acid labile substance to the small intestine.Type: GrantFiled: January 22, 2001Date of Patent: November 12, 2002Inventors: Isa Odidi, Amina Odidi
-
Publication number: 20020160041Abstract: A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation comprising (a) a water insoluble medicament, (b) a high melting fatty ester, (c) a low viscosity oil, (d) a cellulosic polymer, and (e) a non-ionic surfactant.Type: ApplicationFiled: February 21, 2001Publication date: October 31, 2002Inventors: Jose Gutierrez-Rocca, Josephine Dunne, Saul A. Rios
-
Patent number: 6468559Abstract: Oral dosage forms are provided for the administration of a bisphosphonic acid compound in the prevention and treatment of conditions involving calcium or phosphate metabolism, i.e., conditions associated with bone resorption such as osteoporosis, Paget's disease, periprosthetic bone loss, osteolysis, malignant hypercalcemia, metastatic bone disease, multiple myeloma, and periodontal disease. The dosage forms are either enterically coated capsules housing the drug in a liquid or semi-solid carrier, or enterically coated osmotically activated drug delivery devices.Type: GrantFiled: April 28, 2000Date of Patent: October 22, 2002Assignee: Lipocine, Inc.Inventors: Feng-Jing Chen, Mahesh V. Patel
-
Publication number: 20020119192Abstract: A pharmaceutical composition in the form of an oral controlled release solid dosage form comprising an effective amount of drug, or its pharmaceutically acceptable salts. It also relates to a pharmaceutically composition that is suitable for once-a-day dosing regimen.Type: ApplicationFiled: September 21, 2001Publication date: August 29, 2002Inventors: Narayanan Badri Vishwanathan, Rajeev S. Raghuvanshi, Gour Mukherji, Ashok Rampal
-
Publication number: 20020114832Abstract: The invention provides improved pharmaceutical preparations comprising peppermint oil and caraway oil for the treatment of dyspeptic complaints and cramps in the gastrointestinal region. In particularly preferred embodiments, preparations of the invention comprise high dosages of peppermint oil and caraway oil in a delayed-release form which also preferably consists of an enteric-coated soft gelatin capsule. Related methods also are disclosed.Type: ApplicationFiled: December 11, 2000Publication date: August 22, 2002Applicant: Dr. Willmar Schwabe GmbH & Co.Inventors: Joachim Herrmann, Rainer Oschmann, Karl-Heinz Stumpf
-
Patent number: 6436438Abstract: A multiple unit oral pharmaceutical dosage form having a plurality of pellets in a water soluble capsule or in a tablet compressed from the pellets, wherein each pellet contains (a) a substantially inert core, (b) an active ingredient layer over the inert core, and containing (i) a pharmacologically active particulate active ingredient, (ii) a nonembedding amount of a binder for adhering the active ingredient over the inert core, and optionally (iii) a pharmaceutically acceptable, inert adjuvant, such as colloidal silica, and (c) a coating over the active ingredient layer for retarding the release of the active ingredient from the active ingredient layer into an aqueous body fluid solvent in situ, the nonembedding amount of the binder is suitably from about 1% wt. to about 10% wt.Type: GrantFiled: July 8, 1999Date of Patent: August 20, 2002Assignee: Asto-Medica AGInventors: Helmut Momberger, Marc Raber, Dieter Kuhn, Wolfgang Schmid
-
Patent number: 6426088Abstract: The present invention relates to capsules encapsulating antibody-producing cells, and to use of such capsules and encapsulated cells, respectively, for implantation in vivo for long term delivery or sustained delivery of antibodies of therapeutic interest.Type: GrantFiled: June 21, 1999Date of Patent: July 30, 2002Assignees: Bavarian Nordic Research Institute, Centre National de la Recherche ScientifiqueInventors: Marc Piechaczyk, Mireia Pelegrin, Mariana Marin, Robert Saller, Brian Salmons
-
Patent number: 6423339Abstract: A method of producing a free flowing and compressible liquid/power admixture of an active drug substance, by converting the active substance into a liquisolid system. This is accomplished by introducing by the drug into a non-volatile liquid or a mixture of non-volatile and volatile liquids to from a mixture, selecting at least one solid carrier material and admixing these components to produce a non-adherent, free-flowing and compressible liquid/power mass admixture, the amounts of drug and carrier being selected to optimize flow and compressibility.Type: GrantFiled: May 10, 2000Date of Patent: July 23, 2002Inventor: Spiridon Spireas
-
Patent number: 6419954Abstract: The invention provides a tablet and methods for making the tablet comprising a gel-forming material and at least one particle comprising an active agent in contact with a coating material to modify release of the active agent.Type: GrantFiled: May 19, 2000Date of Patent: July 16, 2002Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: James S. Chu, Yisong Yang, Joseph A. Fix
-
Patent number: 6419960Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.Type: GrantFiled: December 16, 1999Date of Patent: July 16, 2002Assignee: Euro-Celtique S.A.Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
-
Publication number: 20020081332Abstract: The present invention relates to a controlled release pharmaceutical composition, suitable for once daily administration, of erythromycin or a derivative thereof and the process for its preparation. More preferably, it relates to a controlled release pharmaceutical composition of clarithromycin suitable for once daily administration.Type: ApplicationFiled: August 29, 2001Publication date: June 27, 2002Inventors: Ashok Rampal, Rajeev S. Raghuvanshi, Manoj Kumar
-
Patent number: 6406703Abstract: The application discloses a method for the treatment of Heliobacter infection in a mammalian host, which comprises administration to said infected host of an immunologically effective amount of one or more Heliobacter antigen(s), optionally in association with a mucosal adjuvant.Type: GrantFiled: July 5, 2000Date of Patent: June 18, 2002Assignees: CSL Limited, The University of New South WalesInventors: Christopher Vincent Doidge, Adrian Lee
-
Patent number: 6403120Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and fiber provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Type: GrantFiled: September 12, 2001Date of Patent: June 11, 2002Assignee: WyethInventors: Deborah M. Sherman, John C. Clark, John U. Lamer, Steven A. White
-
Publication number: 20020044962Abstract: A novel extended or controlled release encapsulated product is provided and includes: at least one active ingredient; at least one erodible polymer; and at least one lubricating material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided.Type: ApplicationFiled: October 19, 2001Publication date: April 18, 2002Inventors: S. Rao Cherukuri, Vittorino Ravelli
-
Patent number: 6368633Abstract: Described are flavor composition, flavor component, perfume composition and perfume component-containing microparticles which are particulate matrices composed of: (a) an olfactorily active component (e.g., perfume component); (b) silica; and (c) a saccharide composition which is a mixture of mannitol and maltose. The microparticles are useful in augmenting, enhancing and/or imparting aroma and/or taste (over relatively long periods of time in a controllably releasable manner) to perfume compositions, perfumed articles (e.g., deodorancy and antiperspirant sticks), foodstuffs, chewing gums, beverages and the like. Also described is a process for preparing the above-mentioned microparticles using, in sequence, (1) adsorption of the olfactorily active material onto silica followed by (2) a blending/extrusion step followed by (3) at least one particularization step.Type: GrantFiled: May 14, 2001Date of Patent: April 9, 2002Assignee: International Flavors & Fragrances Inc.Inventors: Wen Chin Lou, Keith J. McDermott, Shmuel David Shefer, Adi Shefer, John M. Teffenhart, Chee-Teck Tan, Jerome I. Lindauer, Leslie C. Smith
-
Publication number: 20020031546Abstract: A simulated capsule-like medicament comprising a subcoating of a mixture of a water-soluble, film-forming polymer, e.g. hydroxypropylmethyl cellulose and a hydrophobic plasticizer, e.g. castor oil, which promotes a smooth uniform and substantially bubble free outer coating, e.g. gelatin, for the capsule-like medicament; capsule-like medicaments which are slightly bowed in shape; and a process of making such medicaments.Type: ApplicationFiled: October 3, 2001Publication date: March 14, 2002Inventors: Kishor B. Parekh, Dennis C. Wieand, Jean B. Leasure
-
Patent number: 6355609Abstract: Nutritional solutions and methods of making same are disclosed. The solutions include protein, lipid, and a carbohydrate source including high amylose starch and guar gum.Type: GrantFiled: April 14, 1999Date of Patent: March 12, 2002Assignee: Nestec S.A.Inventors: Chandrasekhara Reddy Mallangi, Eileen Fuchs, Kjerstin Carlsson, Axel Syrbe, Reinhard Behringer
-
Publication number: 20020028238Abstract: There is provided a method of rapidly relieving pain in a mammalian, preferably human, subject. The method comprises orally administering to the subject an effective pain-relieving amount of a composition comprising celecoxib formulated in such a way as to provide, when tested in fasting humans in accordance with standard pharmacokinetic practice, a blood plasma concentration profile of celecoxib in which a concentration of about 250 ng/ml is attained not later than about 30 minutes after oral administration.Type: ApplicationFiled: May 25, 2001Publication date: March 7, 2002Inventors: Aziz Karim, Andrew M. Brugger, Ping Gao, Fred Hassan, James C. Forbes
-
Publication number: 20020006438Abstract: The invention is related to a solid sustained release once-a-day oral dosage form comprising hydromorphone or a pharmaceutically acceptable salt thereof together with a sustained release carrier, the dosage providing a relatively rapid rise in plasma concentration to an initial early peak concentration, followed by a second broader peak with plateau plasma concentrations.Type: ApplicationFiled: September 25, 1998Publication date: January 17, 2002Inventors: BENJAMIN OSHLACK, MARK CHASIN, HUA-PIN HUANG
-
Patent number: 6337090Abstract: An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin and a process for making such solid dosage forms are disclosed.Type: GrantFiled: November 13, 2000Date of Patent: January 8, 2002Assignee: Schering CorporationInventors: Stephen M. Liebowitz, Elliot I. Stupak, Imtiaz A. Chaudry, Winston A. Vadino, Frank E. Bowen
-
Publication number: 20020002154Abstract: Methods of treating inflammation of the gastrointestinal tract and/or systemic or local inflammation by administering a steroid anti-inflammatory or a non-steroid anti-inflammatory drug in conjunction with polyunsaturated fatty acids or their derivatives and optionally also a pharmacologically active antioxidant and compositions for practicing these methods are described.Type: ApplicationFiled: February 8, 1999Publication date: January 3, 2002Inventors: POL-HENRI GUIVARC'H, GARY ROBINSON
-
Patent number: 6335032Abstract: An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin is disclosed.Type: GrantFiled: March 6, 2000Date of Patent: January 1, 2002Assignee: Schering CorporationInventors: Stephen M. Liebowitz, Elliot I. Stupak, Imtiaz A. Chaudry, Winston A. Vadino, Frank E. Bowen